Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-MET: 8R-70CAR T Cells for Brain Metastases
NCT07569263Phase 1Recruiting
- Sponsor
- University of Florida
- Start
- Oct 2026
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 8R-70CAR T-cells in brain metastases, sponsored by University of Florida. Primary endpoints: Dose-Limiting Toxicities at 28 days and Proportion of participants who receive an infusion at 10 weeks. Started Oct 2026; status: recruiting.
02
Drugs
8R-70CAR T-cells
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT07569263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07569263.